Intranasal tetrandrine temperature-sensitive in situ hydrogels for the treatment of microwave-induced brain injury.


Journal

International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127

Informations de publication

Date de publication:
15 Jun 2020
Historique:
received: 04 03 2020
revised: 13 04 2020
accepted: 27 04 2020
pubmed: 7 5 2020
medline: 27 2 2021
entrez: 7 5 2020
Statut: ppublish

Résumé

The brain is the most sensitive organ to microwave radiation. However, few effective drugs are available for the treatment of microwave-induced brain injury due to the poor drug permeation into the brain. Here, intranasal tetrandrine (TET) temperature-sensitive in situ hydrogels (ISGs) were prepared with poloxamers 407 and 188. Its characteristics were evaluated, including rheological properties, drug release in vitro, and mucosal irritation. The pharmacodynamics and brain-targeting effects were also studied. The highly viscous ISGs remained in the nasal cavity for a long time with the sustained release of TET and no obvious ciliary toxicity. Intranasal temperature-sensitive TET ISGs markedly improved the spatial memory and spontaneous exploratory behavior induced by microwave with the Morris water maze (MWM) and the open field test (OFT) compared to the model. The ISGs alleviated the microwave-induced brain damage and inhibited the certain mRNA expressions of calcium channels in the brain. Intranasal temperature-sensitive TET ISGs was rapidly absorbed with a shorter T

Identifiants

pubmed: 32371003
pii: S0378-5173(20)30368-9
doi: 10.1016/j.ijpharm.2020.119384
pii:
doi:

Substances chimiques

Benzylisoquinolines 0
Calcium Channel Blockers 0
Calcium Channels 0
Delayed-Action Preparations 0
Hydrogels 0
Stimuli Responsive Polymers 0
Poloxamer 106392-12-5
tetrandrine 29EX23D5AJ

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

119384

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Lihua Zhang (L)

Department of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine, Beijing 100850, China; School of Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250355, China.

Lulu Pang (L)

Department of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine, Beijing 100850, China; School of Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250355, China.

Siqing Zhu (S)

Department of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine, Beijing 100850, China; Anhui Medical University, Hefei 230032, China.

Jinqiu Ma (J)

Department of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine, Beijing 100850, China; School of Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250355, China.

Ruiteng Li (R)

Department of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine, Beijing 100850, China; School of Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250355, China.

Yijing Liu (Y)

Department of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine, Beijing 100850, China; School of Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250355, China.

Lin Zhu (L)

Department of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine, Beijing 100850, China.

Xiaomei Zhuang (X)

Beijing Institute of Toxicology and Pharmacology, No. 27, Taiping Road, Beijing 100850, China.

Weijia Zhi (W)

Department of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine, Beijing 100850, China.

Xiang Yu (X)

Department of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine, Beijing 100850, China; Shenyang Pharmaceutical University, No.103, Wenhua Road, Shenyang 110016, China.

Lina Du (L)

Department of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine, Beijing 100850, China; School of Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250355, China; Anhui Medical University, Hefei 230032, China. Electronic address: dulina@188.com.

Hongyan Zuo (H)

Department of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine, Beijing 100850, China. Electronic address: zuohy2005@126.com.

Yiguang Jin (Y)

Department of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine, Beijing 100850, China; Anhui Medical University, Hefei 230032, China; Shenyang Pharmaceutical University, No.103, Wenhua Road, Shenyang 110016, China. Electronic address: jinyg@sina.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH